Cryoport Leans into Strengths as DHL Deal Advances, Cell & Gene Demand Grows, and Tariffs Test Supply Strategy

In a macro environment shaped by geopolitical uncertainty, rising tariffs, and uneven biotech sentiment, Cryoport (NASDAQ: CYRX) is leaning into its strengths: commercial Cell & Gene therapy logistics, strategic global partnerships, and a sharpened focus on margin expansion. The company delivered Q1 2025 revenue of $41.0 million, up 10% year-over-year, and reaffirmed full-year guidance of $165 to $172 million, despite growing pressure on the supply chain and regulatory front.

On the earnings call, management addressed tariff impacts directly, confirming they've already begun to pass through aluminum-related costs via surcharges while mitigating other risks through strategic sourcing. CEO Jerrell Shelton emphasized that most of Cryoport's critical Cell & Gene workflows remain unaffected by tariffs, as the bulk of activity is patient-specific, U.S.-based, and built on autologous materials.

Strong Service-Led Growth and Product Stabilization

Cryoport's Life Sciences Services segment, now representing 56% of total revenue, grew 17% year-over-year, including 33% growth in commercial Cell & Gene therapy support and 23% growth in BioStorage and BioServices. The company now supports 20 commercial therapies and 711 global clinical trials, a net increase of 36 over the prior year, with expectations for 17 new BLA or MAA filings and up to 8 approvals during the remainder of 2025.

Life Sciences Products revenue also showed signs of stabilization, growing 2% year-over-year. Cryoport cited improving order trends and the launch of the MVE High-Efficiency 800C cryogenic system, built to meet the high-volume needs of space-constrained facilities.

Gross margin improved to 45.4% from 40.4% in Q1 2024, with service margin gains driven by higher volumes and greater client penetration. Operating expenses fell 14% year-over-year, and adjusted EBITDA improved to ($2.8 million) from ($6.7 million) in Q1 2024.

The company ended the quarter with $244 million in cash and short-term investments, and retains $73.9 million in share repurchase authorization.

Analyst Update: Needham Reiterates Buy Amid Margin Recovery and Clear Cell & Gene Tailwinds

Needham & Company reaffirmed its Buy rating and $11 price target, citing the return to growth in Cryoport's MVE Products division, strong momentum in commercial therapy revenue, and increasing visibility into adjusted EBITDA profitability in 2025.

Analysts raised EPS forecasts for 2025 and 2026 and highlighted the company's strategic flexibility following the planned divestiture of CRYOPDP, which is expected to enhance both margin structure and cash reserves. Needham sees long-term upside tied to Cryoport's ability to scale with Cell & Gene therapy approvals while expanding globally through its DHL partnership.

On the Call: Strategic Clarity and Confidence in Execution

During the call, management outlined key indicators of growth, including 32 new trial programs added in Q1, early commercial traction from IntegriCell, and stronger engagement from both new and existing service clients.

CFO Robert Stefanovich noted that gross margin expansion will continue in 2025, while IntegriCell and other scaling initiatives may modestly weigh in the near term. The company expects ongoing improvement in both service and product margins as scale increases.

Management also downplayed concerns around China and trade war dynamics, noting that Cryoport's North American business is resilient, and that most product revenue is domestically manufactured, helping shield the company from cross-border disruptions.

The DHL transaction, expected to close in Q2 or Q3, was described as transformational. It enhances Cryoport's positioning in EMEA and APAC, strengthens its financial profile, and enables a sharper strategic focus on high-margin, high-growth regenerative medicine logistics.

Bottom Line

With improving margins, growing commercial support, and a global logistics partner in place, Cryoport enters the remainder of 2025 focused on executing a high-conviction strategy in Cell & Gene logistics. Despite tariff noise and macro headwinds, the company sees itself as a critical enabler of the regenerative medicine supply chain, and is positioning accordingly.

The post Cryoport Leans into Strengths as DHL Deal Advances, Cell & Gene Demand Grows, and Tariffs Test Supply Strategy appeared first on PRISM MarketView.

COMTEX_465290480/2927/2025-05-08T09:00:38